Your browser doesn't support javascript.
loading
["Diabesity"-Obesity and type 2 diabetes (Update 2019)]. / "Diabesity" ­ Adipositas und Typ-2-Diabetes (Update 2019).
Toplak, Hermann; Leitner, Deborah Raphaela; Harreiter, Jürgen; Hoppichler, Friedrich; Wascher, Thomas C; Schindler, Karin; Ludvik, Bernhard.
Afiliación
  • Toplak H; Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. hermann.toplak@medunigraz.at.
  • Leitner DR; Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
  • Harreiter J; Gender Medicine Unit, Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
  • Hoppichler F; Abteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder Salzburg, Salzburg, Österreich.
  • Wascher TC; Medizinische Abteilung, Hanusch-Krankenhaus, Wien, Österreich.
  • Schindler K; Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
  • Ludvik B; Medizinische Abteilung mit Diabetologie, Endokrinologie und Nephrologie, Krankenanstalt Rudolfstiftung, Wien, Österreich.
Wien Klin Wochenschr ; 131(Suppl 1): 71-76, 2019 May.
Article en De | MEDLINE | ID: mdl-30980154
For several years obesity and type 2 diabetes have been increasingly summarized under the name "diabesity". This is due to the fact that in most cases obesity precedes diabetes and is the most important risk factor for the worldwide increase of type 2 diabetes. The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e. g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and also concomitant treatment is increasingly influenced by body weight. The significance of anti-obesity medications in the treatment of type 2 diabetes will have to be clarified by future studies with body weight as the primary endpoint. Bariatric surgery is at present indicated with a BMI >35 kg/m2 with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Obesidad Tipo de estudio: Guideline / Risk_factors_studies Idioma: De Revista: Wien Klin Wochenschr Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Obesidad Tipo de estudio: Guideline / Risk_factors_studies Idioma: De Revista: Wien Klin Wochenschr Año: 2019 Tipo del documento: Article